Isis, Genzyme Submit Antisense Cholesterol Drug for European Approval
July 28, 2011
* Type size: - +
* ""
* Printer-friendly version
* RSS Feed
Specifically, the companies are seeking clearance to commercialize the 200 mg weekly dose of the drug for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
Once again correct ACE.....
next announcement and likely content, page-138
-
- There are more pages in this discussion • 19 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
